|1.||Bussel, James B: 7 articles (05/2012 - 03/2002)|
|2.||Wiese, Manfred: 4 articles (01/2014 - 10/2005)|
|3.||Brossard, Y: 4 articles (03/2010 - 10/2000)|
|4.||Brossard, Yves: 4 articles (12/2005 - 12/2002)|
|5.||Lazarus, Alan H: 3 articles (06/2015 - 06/2003)|
|6.||Despotovic, Jenny M: 3 articles (11/2013 - 05/2012)|
|7.||Morris, Timothy A: 3 articles (09/2012 - 11/2010)|
|8.||Tarantino, Michael D: 3 articles (05/2012 - 04/2006)|
|9.||Semple, John W: 3 articles (08/2011 - 10/2003)|
|10.||Cooper, Nichola: 3 articles (12/2009 - 03/2002)|
|1.||Thrombocytopenic Purpura (Thrombopenic Purpura)
06/01/2010 - "Efficacy and safety of anti-D for immune thrombocytopenic purpura in children."
01/01/2007 - "Immune thrombocytopenic purpura associated with renal disease is usually therapy-related, occurring after administration of intravenous immunoglobulin therapy or anti-D. "
11/01/2003 - "Use of intravenous anti-D in patients with refractory and relapsed immune thrombocytopenic purpura."
11/01/2003 - "Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care."
03/01/2001 - "A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura."
02/01/1989 - "Routine administration of a small dose (100 micrograms) of anti-D is effective in preventing Rh sensitization after midtrimester amniocentesis."
03/15/1971 - "[Prophylactic efficacy of maternal-fetal RH isoimmunization with a single dose of 200 ug anti-D Ig G]."
04/13/1974 - "Controlled trial of various anti-D dosages in suppression of Rh sensitization following pregnancy. "
11/23/1968 - "A study of the incidence of Rh-sensitization showed a 6.5% incidence of anti-D appearing for the first time during the last trimester of pregnancy. "
10/01/2007 - "The initial range of anti-D immune globulin levels was 24-244 international units, and all women had severe Rh isoimmunization complicating previous pregnancies. "
|3.||Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
11/01/2007 - "Anti-D treatment is effective in increasing platelet (PLT) counts in patients with autoimmune thrombocytopenic purpura (AITP); however, the exact mechanism of action is unknown. "
02/01/2012 - "Idiopathic thrombocytopenic purpura managed by intravenous anti-D."
03/01/2010 - "Evaluation of the effects of and earliest response rate to anti-D treatment in children with chronic idiopathic thrombocytopenic purpura: a pilot study."
12/15/2009 - "Subcutaneous anti-D treatment of idiopathic thrombocytopenic purpura in children."
01/01/2008 - "Rapid encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura."
04/01/2007 - "These data suggest that treatment of severe thrombocytopenia accompanying DHF with anti-D may be a useful and safe therapeutic option."
06/01/2015 - "A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects."
12/01/2013 - "Therefore, intramuscular anti-D given at a dose of 10 mcg/kg for 5 days is an alternative method to raise platelet counts in chronic immune thrombocytopenia children with severe thrombocytopenia where the intravenous form of anti-D is not available."
12/01/2013 - "Nine patients with chronic immune thrombocytopenia and platelet counts <20 × 10(9) /L, with a median age of 7.8 (3.8-15.5) years, received three phases of 10 mcg/kg/dose of intramuscular anti-D. "
12/01/2013 - "Intramuscular anti-D in chronic immune thrombocytopenia children with severe thrombocytopenia."
05/01/2014 - "If a pregnancy is 12 weeks' gestation and the woman is rhesus negative, she will require anti-D prophylaxis if there are symptoms of bleeding. "
01/01/2011 - "Adequate dose calculation of anti-D Ig is possible through estimation of correct feto-maternal hemorrhage (FMH) volume. "
02/01/2006 - "After a first injection of anti-D, if repetition of potential sensitizing events occurs, abstention of prophylaxis is possible depending on the previous administrated dose (protection lasts 6 weeks for 200microg and 9 weeks for 300microg) and the amount of feto-maternal hemorrhage. "
02/01/2006 - "RhD prophylaxis includes targeted prophylaxis (prevention of anti-D immunization after feto-maternal hemorrhage (FMH) induced by prenatal events and delivery) and routine antenatal D prophylaxis (prevention of anti-D immunization resulting from spontaneous FMH in the last trimester of pregnancy). "
06/01/2003 - "This information would suggest that the routine administration of additional anti-D immune globulin (beyond the current recommended protocol) to women who are Rh D-negative whose pregnancies are complicated by third-trimester bleeding is not indicated."
|1.||Inosine Triphosphate (ITP)
|2.||Intravenous Immunoglobulins (IVIG)
|4.||Immunoglobulin G (IgG)
|9.||Muromonab-CD3 (Muromonab CD3)
|10.||HLA-A Antigens (HLA-A)
|1.||Intrauterine Blood Transfusion
|2.||Platelet Transfusion (Blood Platelet Transfusions)